$24.45
6.16% today
Nasdaq, Apr 03, 06:48 pm CET
ISIN
US4158581094
Symbol
HROW
Sector
Industry

Harrow Health, Inc. Stock price

$26.05
+0.42 1.64% 1M
-19.83 43.22% 6M
-7.50 22.35% YTD
+13.67 110.42% 1Y
+18.96 267.42% 3Y
+22.43 619.61% 5Y
+17.96 222.00% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+1.07 4.28%
ISIN
US4158581094
Symbol
HROW
Sector
Industry

Key metrics

Market capitalization $928.79m
Enterprise Value $1.11b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 5.56
P/S ratio (TTM) P/S ratio 4.65
P/B ratio (TTM) P/B ratio 13.32
Revenue growth (TTM) Revenue growth 53.32%
Revenue (TTM) Revenue $199.61m
EBIT (operating result TTM) EBIT $9.08m
Free Cash Flow (TTM) Free Cash Flow $-23.80m
Cash position $47.25m
EPS (TTM) EPS $-0.49
P/E forward 53.16
P/S forward 3.28
EV/Sales forward 3.92
Short interest 11.60%
Show more

Is Harrow Health, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Harrow Health, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

5 Analysts have issued a Harrow Health, Inc. forecast:

5x Buy
100%

Analyst Opinions

5 Analysts have issued a Harrow Health, Inc. forecast:

Buy
100%

Financial data from Harrow Health, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Dec '24
+/-
%
200 200
53% 53%
100%
- Direct Costs 49 49
24% 24%
25%
150 150
66% 66%
75%
- Selling and Administrative Expenses 115 115
61% 61%
57%
- Research and Development Expense 12 12
84% 84%
6%
24 24
82% 82%
12%
- Depreciation and Amortization 15 15
20% 20%
7%
EBIT (Operating Income) EBIT 9.08 9.08
1,019% 1,019%
5%
Net Profit -17 -17
28% 28%
-9%

In millions USD.

Don't miss a Thing! We will send you all news about Harrow Health, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Harrow Health, Inc. Stock News

Neutral
Seeking Alpha
5 days ago
Harrow's stock is down 17% since my last analysis and "Sell" recommendation. Harrow's Q4 and FY24 results show significant revenue growth and improved net income, but the company faces complex reimbursement challenges and tough competition. Valuation models suggest Harrow is fairly valued if it achieves 20% revenue growth and 15% FCF margins, though these are lofty expectations.
Neutral
Seeking Alpha
6 days ago
Harrow, Inc. (NASDAQ:HROW ) Q4 2024 - Earnings Conference Call March 28, 2025 8:00 AM ET Company Participants Jamie Webb - Director, Communications & IR Mark Baum - CEO Andrew Boll - CFO Conference Call Participants Chase Knickerbocker - Craig Hallum Thomas Flaten - Lake Street Capital Markets Jeffrey Cohen - Ladenburg Thalmann and Company Mayank Mamtani - B. Riley Securities Yi Chen - H.
Positive
Seeking Alpha
6 days ago
Harrow, Inc. is a speculative buy, with potential trading gains from the $20s to the $30s, and long-term growth prospects. The company reported strong Q4 growth, with an 84% revenue increase and improved gross profit margins, driven by key products IHEEZO and VEVYE. Harrow's 2025 revenue guidance is bullish, expecting over $280 million, a 40% increase, supported by the VEVYE Access for All prog...
More Harrow Health, Inc. News

Company Profile

Harrow Health, Inc. engages in the development, production, and sale of innovative medications. It operates through the Pharmaceutical Compounding and Pharmaceutical Drug Development segments. The Pharmaceutical Compounding segment focuses on the operations of ImprimisRx business. The company was founded by Mark L. Baum and Robert J. Kammer in January 2006 and is headquartered in Nashville, TN.

Head office United States
CEO Mark Baum
Employees 382
Founded 2006
Website www.harrow.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today